Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome

Abstract

Hemolytic uremic syndrome is a rare disease, frequently responsible for renal insufficiency in children. Recent findings have led to renewed interest in this pathology. The discovery of new gene mutations in the atypical form of HUS and the experimental data suggesting the involvement of the complement pathway in the typical form, open new perspectives for treatment. This review summarizes the current state of knowledge on both typical and atypical hemolytic uremic syndrome pathophysiology and examines new perspectives for treatment.

Keywords: Analogue des récepteurs aux Shiga toxines; Eculizumab; Hemolytic uremic syndrome; Shiga toxin receptor analogues; Syndrome hémolytique urémique; Urtoxazumab.